Skip to main content
OpenTrials
Completed

NCT Number: NCT03326648

The Role of Muscle Protein Breakdown in the Regulation of Muscle Quality in Frail Elderly Individuals

The purpose of this study is to investigate mechanisms underlying the reduction in muscle quality (the ratio between muscle strength and muscle size) with aging, and to investigate how these factors are affected by strength training and protein supplementation. It is already established that muscle quality defined as the ratio between the strength and the size of a muscle is improved with strength training, even in frail elderly individuals. However, the relative contribution of factors such as activation level, fat infiltration, muscle architecture and single fiber function is unknown. The main focus of this study is to investigate the relationship between muscle quality and muscle protein breakdown, as insufficient degradation of proteins is hypothesized to negatively affect muscle quality.

Completed

Looking for future studies?

Notify Me

Key information

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Norwegian School of Sport Sciences

Oslo, 0863, Norway

About this study

Aging is associated with impaired skeletal muscle function. This is evident not only by a reduced capacity to generate force and power at the whole muscle level, but also by a decline in individual muscle fiber contraction velocity and force generation. Combined with muscle atrophy, these changes lead to reduced muscle strength and quality and loss off physical function with age. Clinically, muscle quality may be a better indicator of overall functional capacity than absolute muscle strength. Thus, identifying the mechanisms underlying the age-related loss of muscle quality is of high relevance for the prevention of functional impairment with aging. The explanation for the loss of muscle quality with aging seems to be multifactorial, with alterations in voluntary muscle activation, muscle architecture, fat infiltration and impaired contractile properties of single muscle fibers being likely contributors. Single fiber specific force seems to be related to myosin heavy chain (MHC) content, which is thought to reflect the number of available cross-bridges. The reduction of single fiber specific force with aging may thus be a consequence of reduced synthesis of MHC and/or increased concentration of non-contractile tissue (e.g. intramyocellular lipids).

Some studies in mice also indicate attenuated activity in some of the pathways responsible for degradation of muscle proteins with aging (especially autophagy). As a result, damaged proteins and organelles are not removed as effectively as they should, which could ultimately compromise the muscle's ability to produce force. In addition, reduced efficiency of mitophagy and lipophagy (two specific forms of autophagy), may indirectly affect single fiber specific force, through oxidative damage by reactive oxygen species (ROS) and increased levels of intramyocellular lipids, respectively. Although animal studies indicate attenuated autophagic function, exercise seems to restore the activity in this pathway. Whether this also is the case in humans is unknown. Thus, the purpose of this study is to investigate how the different factors contributing to reduced muscle quality in frail elderly individuals, with emphasis on the relationship between muscle quality and autophagy, may be counteracted by a specific strength training program targeting muscle quality and muscle mass.

In this randomized controlled trial the investigators will aim to recruit frail elderly individuals, as muscle quality is shown to be low in this population. As a consequence, the potential for improved muscle quality is expected to be large. Subjects will be randomized to two groups; one group performing strength training twice a week for 10 weeks in addition to receiving daily protein supplementation. The other group will only receive the protein supplement. Several tests will be performed before and after the intervention period, including a test day where a biopsy is obtained both at rest, and 2.5 hours following strength training + protein supplementation or protein supplementation only. This will provide information about the regulation of muscle protein breakdown in a resting state, following protein intake and following strength training in combination with protein intake. As this will be done both before and after the training period, it will also provide information on how long-term strength training affects the activity in these systems.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 65
  • Frail or pre-frail according to the Fried Frailty Criteria or Short Physical Performance Battery (SPPB) score <6.
  • Mini Mental State Examination score > 18

Exclusion criteria

  • Diseases or injuries contraindicating participation
  • Lactose intolerance
  • Allergy to milk
  • Allergy towards local anesthetics (xylocain)
  • Use of anticoagulants that cannot be discontinued prior to the muscle biopsy

Treatment and study plan

Strength training

Other

Heavy load strength training performed twice a week for 10 weeks.

Other names: Resistance training

Protein supplementation

Dietary Supplement

Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.

Primary outcomes

  1. Single fiber specific force

    Time frame: Change from baseline at 10 weeks

    A measure of muscle quality at the single fiber level. Biopsies obtained from m. Vastus Lateralis

Secondary outcomes

  1. Lean mass

    Time frame: Change from baseline at 10 weeks

    Measured by a Dual-energy X-ray absorptiometry (DXA) scan

  2. Fat mass

    Time frame: Change from baseline at 10 weeks

    Measured by a Dual-energy X-ray absorptiometry (DXA) scan

  3. Bone mineral density

    Time frame: Change from baseline at 10 weeks

    Measured by a Dual-energy X-ray absorptiometry (DXA) scan

  4. Muscle strength of m. quadriceps

    Time frame: Change from baseline at 10 weeks

    Maximal isometric and dynamic muscle strength of m. quadriceps

  5. Muscle size of m. quadriceps

    Time frame: Change from baseline at 10 weeks

    Cross-sectional area of m. quadriceps measured by a Computed Tomography scan

  6. Fat infiltration of m. quadriceps

    Time frame: Change from baseline at 10 weeks

    Fat infiltration of m. quadriceps measured by a Computed Tomography scan

  7. Muscle activation

    Time frame: Change from baseline at 10 weeks

    Voluntary activation level during a maximal isometric knee extension using the interpolated twitch technique

  8. Fractional Breakdown Rate

    Time frame: Measured over the last 14 days of the intervention period

    Measurement of fractional breakdown rate by the use of orally provided Deuterium Oxide, biopsies and blood samples

  9. m. Vastus Lateralis thickness

    Time frame: Change from baseline at 10 weeks

    Measured by ultrasound

  10. Chair stand performance

    Time frame: Change from baseline at 10 weeks

    Time (sec) to stand up from a chair five times

  11. Habitual gait velocity

    Time frame: Change from baseline at 10 weeks

    Time (sec) to walk 6 meters at habitual gait velocity

  12. Maximal gait velocity

    Time frame: Change from baseline at 10 weeks

    Time (sec) to walk 6 meters as fast as possible

  13. Level/cellular location of Microtubule-associated protein 1A/1B-light chain 3 (LC3)

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  14. Level/cellular location of p62/Sequestosome-1

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  15. Level/cellular location of Lysosome-associated membrane glycoprotein 2 (LAMP2)

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  16. Level/cellular location of forkhead box O3 (FOXO3a)

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  17. Phosphorylation status and total level of ribosomal protein S6 kinase beta-1(P70S6K)

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  18. Phosphorylation status and total level of eukaryotic elongation factor 2 (eEF-2)

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  19. Phosphorylation status and total level of eukaryotic translation initiation factor 4E-binding protein 1 (4EBP-1)

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  20. Level/cellular location of muscle RING-finger protein-1 (Murf-1)

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  21. Level/cellular location of ubiquitin (Ub)

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  22. Blood serum glucose

    Time frame: Change from baseline at 10 weeks

    Fasted

  23. Blood serum insulin

    Time frame: Change from baseline at 10 weeks

    Fasted

  24. Blood plasma Hemoglobin A1c (HbA1c)

    Time frame: Change from baseline at 10 weeks

    Fasted

  25. Blood serum Triglycerides

    Time frame: Change from baseline at 10 weeks

    Fasted

  26. Blood serum High-density lipoproteins (HDL)

    Time frame: Change from baseline at 10 weeks

    Fasted

  27. Blood serum Low-density lipoproteins (LDL)

    Time frame: Change from baseline at 10 weeks

    Fasted

  28. Blood serum C-reactive protein (CRP)

    Time frame: Change from baseline at 10 weeks

    Fasted

  29. forkhead box protein O3 (FOXO3A) mRNA

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  30. forkhead box protein O1 (FOXO1) mRNA mRNA

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  31. hepatocyte growth factor (HGF) mRNA

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  32. insulin-like growth factor I (IGF1) mRNA

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  33. myostatin (MSTN) mRNA

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  34. E3 ubiquitin-protein ligase TRIM63 (TRIM63) mRNA

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  35. p62/Sequestosome-1 mRNA

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  36. muscle RING-finger protein-1 (Murf-1) protein 1 (4EBP-1) mRNA

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  37. Atrogin1 mRNA

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  38. Microtubule-associated protein 1A/1B-light chain 3 (LC3) mRNA

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  39. BCL2/adenovirus E1B interacting protein 3 (BNIP3) mRNA

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  40. PTEN-induced putative kinase 1 (PINK1) mRNA

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  41. TNF receptor associated factor 6 (TRAF6) mRNA

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  42. transcription factor EB (Tfeb) mRNA

    Time frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks

    Biopsies from m. Vastus Lateralis analyzed by western blot

  43. Intramyocellular lipids

    Time frame: Change from baseline at 10 weeks

    Oil-Red-O staining of muscle sections. Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry

  44. Muscle fiber type distribution

    Time frame: Change from baseline at 10 weeks

    Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry

  45. Muscle fiber cross-sectional area

    Time frame: Change from baseline at 10 weeks

    Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry

  46. Muscle satellite cells

    Time frame: Change from baseline at 10 weeks

    Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry

  47. Myonuclei

    Time frame: Change from baseline at 10 weeks

    Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry

  48. Myonuclei number

    Time frame: Change from baseline at 10 weeks

    Biopsy from m. Vastus Lateralis analyzed by confocal microscopy

  49. Myonuclei location

    Time frame: Change from baseline at 10 weeks

    Biopsy from m. Vastus Lateralis analyzed by confocal microscopy

  50. Amount of mitochondria

    Time frame: Change from baseline at 10 weeks

    Biopsy from m. Vastus Lateralis analyzed by confocal microscopy

  51. Location of mitochondria

    Time frame: Change from baseline at 10 weeks

    Biopsy from m. Vastus Lateralis analyzed by confocal microscopy

Sponsors and collaborators

Lead sponsor

Truls Raastad

Other

Collaborators

  • Tine
  • University of Copenhagen
  • University of Padova

Registry information

Important dates

Study start
2016
Primary completion
2017
Study completion
2018
First posted
Oct 31, 2017
Registry last updated
Apr 11, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.